Education

This first module in the series of Breaking the Monoamine Barrier will focus on describing the limitations of conventional monoaminergic antidepressants that are associated with suboptimal treatment outcomes in MDD.

In Module 2 of Breaking the Monoamine Barrier, Dr. Craig Chepke will outline the evolving neuroscientific understanding of the glutamatergic system in the pathophysiology of MDD, as well as explore the mechanisms of action and pharmacologic characteristics of glutamatergic antidepressants for MDD.

Assess the latest clinical data associated with the efficacy, tolerability, and safety of glutamatergic antidepressants for MDD in this third module of Breaking the Monoamine Barrier with Kristian Dambrino, MSN, APRN, PMHNP-BC. 

In the final module of Breaking the Monoamine Barrier, Craig Chepke discusses how to make informed treatment decisions regarding glutamatergic antidepressants for patients with MDD on the basis of available clinical evidence and guidance.

This activity focuses on optimizing the management of major depressive disorder (MDD) by addressing residual symptoms and side effects associated with conventional antidepressants. Participants will review the latest data on precision serotonin receptor modulators, their mechanisms of action, and strategies for antidepressant selection and switching to enhance outcomes through shared decision-making and collaborative care.